MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

407 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-04-30

Study Completion Date

2007-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A study to determine lipid changing effects of MK0524A when compared to niacin extended release (NIASPAN) and placebo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)

NCT00378833

Hypercholesterolemia Hyperlipidemia

COMPLETED PHASE3

Lipid Efficacy/Tolerability Study (0524A-020)

NCT00269204

Primary Hypercholesterolaemia Mixed Hyperlipidaemia

COMPLETED PHASE3

Effect of MK0524A on Cholesterol Levels (0524A-048)

NCT00536510

Hypercholesterolemia Hyperlipidemia

COMPLETED PHASE3

MK0524A Phase IIb Study (0524A-011)(COMPLETED)

NCT00536237

Flushing

COMPLETED PHASE2

Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)

NCT00376584

Hypercholesteremia Hyperlipidemia

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypercholesterolemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Comparator : placebo (unspecified) / Duraton of Treatment: 4 Weeks

Intervention Type DRUG

MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks

Intervention Type DRUG

Comparator : niacin / Duraton of Treatment: 4 Weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must be between the ages of 18 and 70 years
* Female patients must be pre-menopausal women that have been surgically sterilized, not pregnant and/or not planning to become pregnant

Exclusion Criteria

* Patient has a history of peptic ulcer or gout
* Patient is sensitive to niacin or products containing niacin
* Patient drinks more than 2 alcoholic drinks per day
* Patient has certain heart disease, cancer, or is HIV positive

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No